OphthaliX, a clinical-stage biotech developing treatments for ophthalmic disorders, withdrew its plans for an initial public offering on Tuesday. It originally filed in July 2013 with a proposed deal size of $10 million.
The Petach Tikva, Israel-based company was founded in 1999 and had planned to list on the NYSE. Maxim Group LLC was set to be the sole bookrunner on the deal.
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
